IE85834B1 - Varicella-zoster virus antigen - Google Patents
Varicella-zoster virus antigenInfo
- Publication number
- IE85834B1 IE85834B1 IE1991/3479A IE347991A IE85834B1 IE 85834 B1 IE85834 B1 IE 85834B1 IE 1991/3479 A IE1991/3479 A IE 1991/3479A IE 347991 A IE347991 A IE 347991A IE 85834 B1 IE85834 B1 IE 85834B1
- Authority
- IE
- Ireland
- Prior art keywords
- vzv
- cells
- polypeptide
- gpl
- host
- Prior art date
Links
- 241000701085 Human alphaherpesvirus 3 Species 0.000 title claims abstract description 157
- 239000000427 antigen Substances 0.000 title claims description 20
- 102000038129 antigens Human genes 0.000 title description 12
- 108091007172 antigens Proteins 0.000 title description 12
- 108090001123 antibodies Proteins 0.000 claims abstract description 92
- 102000004965 antibodies Human genes 0.000 claims abstract description 92
- 230000003248 secreting Effects 0.000 claims abstract description 45
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 26
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 26
- 230000004044 response Effects 0.000 claims abstract description 20
- 210000004962 mammalian cells Anatomy 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 210000004027 cells Anatomy 0.000 claims description 76
- 229920001184 polypeptide Polymers 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 29
- 229960005486 vaccines Drugs 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 208000007514 Herpes Zoster Diseases 0.000 claims description 20
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 19
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 17
- 210000002966 Serum Anatomy 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 16
- 210000001519 tissues Anatomy 0.000 claims description 15
- 206010046980 Varicella Diseases 0.000 claims description 12
- 201000006082 chickenpox Diseases 0.000 claims description 12
- 108020004511 Recombinant DNA Proteins 0.000 claims description 9
- 230000000890 antigenic Effects 0.000 claims description 9
- 238000002649 immunization Methods 0.000 claims description 8
- 239000000969 carrier Substances 0.000 claims description 7
- 210000003292 kidney cell Anatomy 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 241000282693 Cercopithecidae Species 0.000 claims description 4
- 230000004936 stimulating Effects 0.000 claims description 4
- 241000867607 Chlorocebus sabaeus Species 0.000 claims description 3
- 241000699800 Cricetinae Species 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims 2
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 238000004166 bioassay Methods 0.000 abstract description 20
- 238000010276 construction Methods 0.000 abstract description 13
- 238000001514 detection method Methods 0.000 abstract description 13
- 230000001939 inductive effect Effects 0.000 abstract description 8
- 241000700618 Vaccinia virus Species 0.000 description 24
- 201000009910 diseases by infectious agent Diseases 0.000 description 14
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 239000006166 lysate Substances 0.000 description 9
- 108010045030 monoclonal antibodies Proteins 0.000 description 8
- 102000005614 monoclonal antibodies Human genes 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 239000002609 media Substances 0.000 description 7
- 229960000060 monoclonal antibodies Drugs 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000012531 culture fluid Substances 0.000 description 6
- 229920002401 polyacrylamide Polymers 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 229940088598 Enzyme Drugs 0.000 description 5
- 230000001809 detectable Effects 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000009007 Diagnostic Kit Methods 0.000 description 4
- 230000002238 attenuated Effects 0.000 description 4
- 108091006028 chimera Proteins 0.000 description 4
- 230000000295 complement Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 3
- 210000004899 C-terminal region Anatomy 0.000 description 3
- 206010014599 Encephalitis Diseases 0.000 description 3
- 210000004897 N-terminal region Anatomy 0.000 description 3
- ZHSGGJXRNHWHRS-VIDYELAYSA-N Tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000004873 anchoring Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000005591 charge neutralization Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002860 competitive Effects 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 230000001264 neutralization Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- 108091007521 restriction endonucleases Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- NTQDELBZOMWXRS-UHFFFAOYSA-N Aspartyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CC(O)=O NTQDELBZOMWXRS-UHFFFAOYSA-N 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- IEFJWDNGDZAYNZ-BYPYZUCNSA-N Gly-Glu Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(O)=O IEFJWDNGDZAYNZ-BYPYZUCNSA-N 0.000 description 2
- 210000000987 Immune System Anatomy 0.000 description 2
- DRCKHKZYDLJYFQ-UHFFFAOYSA-N Isoleucyl-Threonine Chemical compound CCC(C)C(N)C(=O)NC(C(C)O)C(O)=O DRCKHKZYDLJYFQ-UHFFFAOYSA-N 0.000 description 2
- 101710026288 MG318 Proteins 0.000 description 2
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 2
- 101700040793 NDE1 Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010035742 Pneumonitis Diseases 0.000 description 2
- 206010036376 Post herpetic neuralgia Diseases 0.000 description 2
- 101710012186 SLC7A1 Proteins 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000007089 Vaccinia Diseases 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 210000002845 Virion Anatomy 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
- 244000052616 bacterial pathogens Species 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 108091008117 polyclonal antibodies Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 210000000605 viral structures Anatomy 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- LINMATFDVHBYOS-MBJXGIAVSA-N (2S,3R,4S,5R,6R)-2-[(5-bromo-1H-indol-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C=C12 LINMATFDVHBYOS-MBJXGIAVSA-N 0.000 description 1
- CUJMXIQZWPZMNQ-XYYGWQPLSA-N 13,14-dihydro-15-oxo-prostaglandin E2 Chemical compound CCCCCC(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CUJMXIQZWPZMNQ-XYYGWQPLSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl dihydrogen phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- GZAJOEGTZDUSKS-UHFFFAOYSA-N 6-amino-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(N)=CC=C21 GZAJOEGTZDUSKS-UHFFFAOYSA-N 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-M AC1L4ZKD Chemical compound [O-]I(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-M 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GADKFYNESXNRLC-WDSKDSINSA-N Asn-Pro Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GADKFYNESXNRLC-WDSKDSINSA-N 0.000 description 1
- CKAJHWFHHFSCDT-WHFBIAKZSA-N Asp-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O CKAJHWFHHFSCDT-WHFBIAKZSA-N 0.000 description 1
- HSPSXROIMXIJQW-BQBZGAKWSA-N Asp-His Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 HSPSXROIMXIJQW-BQBZGAKWSA-N 0.000 description 1
- OAMLVOVXNKILLQ-BQBZGAKWSA-N Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O OAMLVOVXNKILLQ-BQBZGAKWSA-N 0.000 description 1
- YZQCXOFQZKCETR-UWVGGRQHSA-N Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YZQCXOFQZKCETR-UWVGGRQHSA-N 0.000 description 1
- SJUXYGVRSGTPMC-UHFFFAOYSA-N Asparaginyl-Alanine Chemical compound OC(=O)C(C)NC(=O)C(N)CC(N)=O SJUXYGVRSGTPMC-UHFFFAOYSA-N 0.000 description 1
- QJMCHPGWFZZRID-UHFFFAOYSA-N Asparaginyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CC(N)=O QJMCHPGWFZZRID-UHFFFAOYSA-N 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N Bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N Bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 229950004398 Broxuridine Drugs 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010038061 Chymotrypsinogen Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940009976 Deoxycholate Drugs 0.000 description 1
- 108010015776 EC 1.1.3.4 Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 230000035693 Fab Effects 0.000 description 1
- 229940116332 GLUCOSE OXIDASE Drugs 0.000 description 1
- 210000003594 Ganglia, Spinal Anatomy 0.000 description 1
- UQHGAYSULGRWRG-WHFBIAKZSA-N Glu-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(O)=O UQHGAYSULGRWRG-WHFBIAKZSA-N 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- SCCPDJAQCXWPTF-VKHMYHEASA-N Gly-Asp Chemical compound NCC(=O)N[C@H](C(O)=O)CC(O)=O SCCPDJAQCXWPTF-VKHMYHEASA-N 0.000 description 1
- KGVHCTWYMPWEGN-FSPLSTOPSA-N Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CN KGVHCTWYMPWEGN-FSPLSTOPSA-N 0.000 description 1
- OLIFSFOFKGKIRH-WUJLRWPWSA-N Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CN OLIFSFOFKGKIRH-WUJLRWPWSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- SENJXOPIZNYLHU-IUCAKERBSA-N Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-IUCAKERBSA-N 0.000 description 1
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 108010060534 MSH (11-13) Proteins 0.000 description 1
- QXOHLNCNYLGICT-YFKPBYRVSA-N Met-Gly Chemical compound CSCC[C@H](N)C(=O)NCC(O)=O QXOHLNCNYLGICT-YFKPBYRVSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003505 Myosin family Human genes 0.000 description 1
- 108060008487 Myosin family Proteins 0.000 description 1
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N O-Phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 229940092253 Ovalbumin Drugs 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 102100012174 PIWIL2 Human genes 0.000 description 1
- 101710043199 PIWIL2 Proteins 0.000 description 1
- 229940072417 Peroxidase Drugs 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010065081 Phosphorylase b Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- OIDKVWTWGDWMHY-RYUDHWBXSA-N Pro-Tyr Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=C(O)C=C1 OIDKVWTWGDWMHY-RYUDHWBXSA-N 0.000 description 1
- 206010037844 Rash Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- BWUHENPAEMNGQJ-ZDLURKLDSA-N Thr-Gln Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O BWUHENPAEMNGQJ-ZDLURKLDSA-N 0.000 description 1
- CKHWEVXPLJBEOZ-UHFFFAOYSA-N Threoninyl-Valine Chemical compound CC(C)C(C(O)=O)NC(=O)C(N)C(C)O CKHWEVXPLJBEOZ-UHFFFAOYSA-N 0.000 description 1
- NUIURNJTPRWVAP-UHFFFAOYSA-N Tolidine Chemical compound C1=C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 NUIURNJTPRWVAP-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- QZOSVNLXLSNHQK-UHFFFAOYSA-N Tyrosyl-Aspartate Chemical compound OC(=O)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 QZOSVNLXLSNHQK-UHFFFAOYSA-N 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- WITCOKQIPFWQQD-FSPLSTOPSA-N Val-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O WITCOKQIPFWQQD-FSPLSTOPSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(E)-octadec-9-enoyl]oxypropyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- DHRJOYDLBMLIFJ-UHFFFAOYSA-N cresyl violet Chemical compound C1=CC=C2C3=NC4=CC=C(N)C=C4[O+]=C3C=C(N)C2=C1 DHRJOYDLBMLIFJ-UHFFFAOYSA-N 0.000 description 1
- 230000000120 cytopathologic Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- KGNSGRRALVIRGR-UHFFFAOYSA-N gln-tyr Chemical compound NC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 KGNSGRRALVIRGR-UHFFFAOYSA-N 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 108010000761 leucylarginine Proteins 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- 230000036963 noncompetitive Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 230000000644 propagated Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000405 serological Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- IOUPEELXVYPCPG-UHFFFAOYSA-N val-gly Chemical compound CC(C)C(N)C(=O)NCC(O)=O IOUPEELXVYPCPG-UHFFFAOYSA-N 0.000 description 1
- 108010084803 varicella-zoster virus glycoprotein IV Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- OPINTGHFESTVAX-UHFFFAOYSA-N γ-glutamyl-Arginine Chemical compound NC(=O)CCC(N)C(=O)NC(C(O)=O)CCCNC(N)=N OPINTGHFESTVAX-UHFFFAOYSA-N 0.000 description 1
- NJMYZEJORPYOTO-UHFFFAOYSA-N γ-glutamyl-Proline Chemical compound NC(=O)CCC(N)C(=O)N1CCCC1C(O)=O NJMYZEJORPYOTO-UHFFFAOYSA-N 0.000 description 1
Abstract
ABSTRACT The present invention relates to the construction of a recombinant plasmid which is capable of expressing a secretory truncated glycoprotein (T99) of Varicella-zoster virus (VZV) in mammalian cells.’ The secretory Tgp of the present invention contains at-1east~one epitope-capable of inducing antibody response; "The present inventionv contemplates the production and utilization of this secretory - The present invention is also directed towards the use of the secretory Tgp in diagnostic assays for detection of VZV.~ The present invention is also directed to first antibodies ' specific to secretory Tgp and to second antibodies specific to the first antibodies. These.second antibodies are also useful in diagnostic assays for VZV.
Description
VARICELLA-ZOSTER VIRUS ANTIGEN The present invention relates to the construction of a recombinant plasmid which is capable of expressing a secretory truncated glycoprotein (T99) of Varicella-zoster virus (VZV) in mammalian cells.’ The secretory Tgp of the present invention contains at-1east~one epitope-capable of inducing antibody response; "The present inventionv contemplates the production and utilization of this secretory - The present invention is also directed towards the use of the secretory Tgp in diagnostic assays for detection of VZV.~ The present invention is also directed to first antibodies ' specific to secretory Tgp and to second antibodies specific to the first antibodies. These.second antibodies are also useful in diagnostic assays for VZV.
Varicella-zoster virus is the causative agent of childhood chickenpox (varicella) and shingles tzoster), two distinct clinical manifestations. Varicella is the outcome of the primary encounter (infection) with VZV, whereas zoster is the result of VZV reactivation which occurs predominantly in aging and immunosuppressed individuals, including cancer and AIDS patients.
Tgp in a Vaccine against chickenpox and/or shingles.
There are 2.5 million estimated cases of chickenpox and 1.2 million cases of shingles per year in the united States. It is expected that the number of shingles patients will increase as the population ages. one of the most common complications of shingles includes postherpetic neuralgia which is characterized by interactable pain lasting for four weeks to several years after the onset of skin rash. other complications of VZV reactivation (shingles) include encephalitis, pneumonitis and disseminated zoster.
VZV is a member of the alpha herpesvirus family.
VZV contains a linear double—stranded DNA genome of approximately 125,000 base pairs and consists of the sequence of a long unique (U1)—inverted short repeat (IRs)—short unique (Us)rtermina1 short repeat (TRs). VZV DNA encodes five glycoproteins, designated gpl, gpII, gpIII;'gpIV and s mediated immune response in the infected individuals (Davison, et a1., supra, 1986). __ gpI or result in steric hindrances which influence the antigenic determinant recognized by anti—peptide antibodies.
An attenuated varicella—zoster virus vaccine has been used in Japan against chickenpox infection in leukemic children as well as for routine.vaccination in early childhood. This vaccine is currently being tested in the United States in children with leukemia and is expected to be used in healthy children and_for the-prevention of vzv ‘ ,reactivation (shingles) in the elderly population. .Although ; the attenuated varicella vaccine-hesfiheen shown to be safe , and effective.in inducing immunity again$t VZVminfe¢ti0n3 however, similar to_natural infection. attenuated varice11a_ vaccine becomes latent in human dorsal root ganglia and may- reactivate to produce shingles with its attendant neurolggic complications of postherpetic neuralgia and encephalitis.
Therefore, a subunit vaccine which would_avoid and . eliminate latency is desirable for immunization of children as well as for boosting immune response in the elderly who are more susceptible to VZV reactivation_(shing1es), Such subunit vaccine as contemplated by the present invention may be prepared by construction of recombinant viruses (e.g., vaccinia virus) expressing one or more VZV glycoproteins or, as particularly contemplated by the present invention, may be composed of secretory highly immunogenic VZV glycoprotein(s) which can be prepared and purified in large quantities and used for immunization and/or boosting the immune response against VZV infection. In addition, such highly purified VZV glycoproteins can be used as a diagnostic tool for the assessment of the immune status to VZV infection in immunosuppressed individuals (leukemic children, AIDS and cancer patients) as well as in vaccinated individuals and elderly population.
The gene for VZV gpl has been previously isolated, inserted into a plasmid and incorporated into a vaccinia virus expression system. Although gpI protein was produced by the vaccinia expression system, the product remained . within the cells and was therefore unsuitable for eliciting: an antigenic response in-gigg. . p p j The innovation of the present invention resides in" the construction of an expression vector which produces an truncated form of VZV gp which is secretedgfromamammaliand cells.
I. The applications of the present recombinant vaccinia viruses expressing secretoryrtruncated-VzV~ glycoproteins containing one or more highly immunogenic viral epitopes include: (1) using such recombinant viruses as subunit vaccines against Vzvtinfection; wherein secretion of ::; VZV glycoproteins following vaccination provides a stronger imune response to VZV glycoproteins as well as to VZV infection; (2) using large quantities of highly purified and immunogenic secretory VZV glyooproteins containing one or more epitopes as a subunit vaccine against primary VZV infection (chickenpox) in healthy children as well as in immunocompromised individuals and for boosting imunity against VZV reactivation (shingles) in the elderly; and (3) "using purified preparations of secretory truncated VZV glycoproteins in diagnostic kits as highly specific target antigens for the detection and assessment of antibody status to VZV glycoproteins.. since VZV reactivation is common in cancer and AIDS patients, there is also a need for the serological diagnosis of VZV infection in these patients. In addition, since VZV reactivation in the growing population of elderly individuals results in pain prior to the onset of clinical symptoms and may also result in encephalitis, pneumonitis and disseminated zoster, the only hope for an early treatment of these patients lies in a rapid means of diagnosis. Application of the present recombinantly prepared secretory VZV glycoproteins in diagnostic kits can provide a rapid and . inexpensive means for diagnosis of VZV infection.
A The ‘present invention is directed to an expression vector for secretory truncated VZV gp andvconstruction of said vector which permits extracellular secretion of the VZV protein.
More specifically, the present invention is directed to a recombinant DNA expression vector comprising a nucleotide sequence capable of expressing in an infected, transfected or -transformed host a mature polypeptide. said polypeptide being selected from the group consisting of: the 159 amino acid sequence of SEQ ID NO:1, the 511 amino acid sequence of SEQ" ID NO:2, a 276 amino acid sequence defined by an EcoPllEcoRI double digest of a DNA fragment spanning nucleotides ’115712,to 118181 of glycoprotein I of Varicella-zostervirus and containing gpl open reading frame, a 316 amino acid sequence defined by a 'BstE2/EcoRl double digest of a DNA fragment spanning nucleotides 115712 to 118181 of glycoprotein I of Varicella-zoster virus and containing gpl open reading frame, a 341 amino acid sequence defined by an Ndel/EcoR| doubt digest of a DNA fragment spanning nucleotides 115712 to 118181 of glycoprotein I of Variceila-zoster virus and containing gpl open reading frame, or a 408 amino acid sequence defined by an EcoR| single digest of a DNA fragment spanning nucleotides 115712 to 118181 of glycoprotein I of Varicella-zoster virus and containing gpl open reading frame, and wherein said polypeptide is capable of being secreted extraceilularly from said host and is capable of causing a VZV antibody response in mammais.
Another aspect of this invention contemplates a plasmid encoding a Variceila- zoster virus polypeptide said polypeptide being selected from the group’ set out above, and wherein said polypeptide is capable of being secreted extraoeiluiarly from a host and is capable of causing a VZV antibody response in a mammal.
A furthet aspect of the present invention is directed to a process for producing a secretory truncated Varicella-zoster virus glycoprotein wherein the glycoprotein is a polypeptide selected from the group set out above, and wherein said polypeptide is capable of causing a VZV antibody response in mammals, said process comprising the steps of:- a) providing a vector comprising a nucleotide sequence coding for said polypeptide, wherein the nucleotide sequence is capabie of being expressed by a host containing the vector; b) incorporating the vector into the host; and _ c) maintaining the host containing the vector under conditions suitabie for expression of the nucleotide sequence into said glycoprotein.
Yet another aspect of the present invention relates to a recombinant secretory truncated VZV gpl being a polypeptide selected from the group set out above, and wherein said polypeptides are secreted extracellularly from mammalian cells within which said polypeptides are produced and wherein said polypeptides include at least one antigenic epitope capable of eliciting an antibody response in a mammalian host.
Still another aspect of the present invention is the use of secretory truncated VZV gp being a polypeptide selected from the group set out above for the manufacture of a vaccine_ for stimulating an immune response to chickenpox and/or shingles. l ‘ Yet another aspect of this invention contemplates a method of diagnosing.
VZV comprising contacting serum, tissue or tissue extracts of an individual to be tested with an antibody against a secretory truncated VZV gp being a polypeptide selected from the group set out above for a time and under conditions necessary to form an antibody-antigen complex, and detecting any resultant antibody—antigen complex. g Fig. 1 is a schematic representation of the construction of a recombinant plasmid carrying a truncated VZV gpl gene having the e1 epitope. VZV gpl gene cloned in pGEM-'4 transcription vector (Vafai, et al., supra, 1988) was cleaved with Bgill (B) restriction enzyme downstream from e1 epitope and with l_E.c_>o'Rl (E) in the pGEM polyiinker. The truncated gpl gene was electroeluted, blunt-ended and cloned at the Smal (S) of vaccinia virus insertion vector pSC11 as described in detail in the Examples.
Fig. 2 demonstrates expression of a truncated VZV gpl by recombinant vaccinia virus. BSC-1 cells were infected with recombinant vaccinia virus carrying a truncated VZV gpl, as described in Fig. 2, (designated VV'l'gplBglll) and containing e1 epltope. After 22 hours, infected cells were labelled with [35S} methionine for 1 hour and cell Iysates were prepared as described in the Examples. Cell lysates were immunoprecipitated with the following monoclonal antibodies (MAbs) and a human serum and analysed by SDS-12% polyacrylamide PAGE:MAb79.7, directed against e1 epitope; human serum (H-serum) from a VZV seropositive individual; MAbCt, directed against VZV gpl and recognizing epitope(s) other than e1; MabG7, directed against \/ZV gpl and recognizing only the glycosylated form of et epitope; MAbG6, directed against VZV gplV; MAbF8, directed against VZV gpll: and MAbE10, directed against VZV gplll. The size (in kiiodaltons) of precursor and glycosylated form of the Tgp|Bg||l are shown on the left.
Fig. 3 demonstrates expression and secretion of Tgp|Bg|ll from the infected cells. In the left panel, cells were infected with VVTgplBg|l| and after 22 hours, infected cells were pulse-labelled with [358] methionine (300 poi/ml) for 10 min. Cells were either harvested or washed with serum-free medium and the label was chased for 1, 2, 3 and 7 hours. Uninfected cells (Un) were pulse-labelled for 10 min. and chased_,tor 7 hours. Cell lysates (CL) were prepared and imrnunoprecipitated with MAb79.7 (a) which is directed against VZV gpl e1 epitope and MADC1 (b) which is directed against VZV gpl but only recognizes epitope(s) other than e1. Right panel, tissue culture fluid (TCF) from uninfected (Un) and VVTgplBgIll-infected cell chased for '1, 2-, 3 and 7 hours, were immunoprecipitated with MAb79.7(a) and MAbC1 (b).
Samples were analysed by SDS-12% polyacrylamide PAGE as described in materials and methods. Apparent sizes (in kiiodaltons) of ‘precursor and glycosylated mature forms of Tgpl are shown.
Fig. 4 demonstrates expression of recombinant vaccinia virus carrying a full- size VZV gpl gene (designated Wgpl). Cells were infectedwith Wgpl (Cabirac, et al., 1988) and after 22 hours, cells were pulse-chased as described in Fig. 3 and cell Iysates"(CL) and tissue culture fluids (TCF) from uninfected (Un) and Wgpl-infected cells (vvgpl) were immunoprecipitated with MAb79.7 which is directed against VZV gpl e1 epitope. Samples were analysed by SDS-8% polyacrylamide PAGE as described in the Examples. The size-range of precursor-products of VZV gpl (Vafai, et al., 19:38) is indicated.
Fig. 5 demonstrates immunoprecipitation of VZV-infected cells with rabbit antibodies prepared against recombinant vaccinia virus carrying a truncated VZV gpl and containing e1 epitope (VVTgpl). Cells were infected with .VZV and after 48 hours, cells were pulse-labelled with [353] methionine (300 uci/ml) for 10 min. in the absence or presence of (15 pg/ml) tunicamycin (T M), which inhibits the addition of N- linked oligosaccharides to native VZV gpl. Cells were either harvested or washed and chased for 2 hours in the absence or presence of TM (15pg/ml). Cell lysates were prepared and immunoprecipitated with MADC1 (a) which recognizes both VZV gpl and gplv and rabbit anti-VVTgpl antibodies (FiAnti-VVTgp|). Samples were analysed by SDS-8% polyacrylamide PAGE as described in the Examples. Apparent sizes (in kilodaltons) or precursor-products of VZV gpl and gplv (Vafai, et al., supra, 1938) are indicated on the right. Lysozyme (14.3 kDa), [3-Iactoglobulin (18.4 kDa); oi- chymotrypsinogen (25.7 kDa), ovalbumin (43.0 kDa), bovine serum albumin (68.0 kDa), phosphorylase B (97.4 kDa), and myosin (200.0 kDa) were used as internal size markers. ' The present invention contemplates the construction of a recombinant plasmid having a truncated VZV gp (3, II, III, IV or V) gene carrying at least one epitope capable of inducing antibody response in mammalian cells. In particular, the present‘invention-relates to a vaccinia virus expression system capable of producing truncated VZV gp which can be secreted from mammalian cells into a host organism in mm) In one embodiment, the present invention contemplates the construction of a recombinant plasmid having a secretory truncated VZV gpl (referred to as TgplBglll or VV'l'gplBgl|l) carrying e1 epitope and production of said protein by the vaccinia virus expression vector in mammalian cells as described herein.
In another embodiment, the present invention contemplates the construction of a recombinant plasmid having a secretory truncated VZVgp| (referred to as Tgplxmalll or VVTgplXmalll) and production of said protein by the vaccinia virus expression vector in mammalian cells as described herein.
In another embodiment-, this invention contemplates the preparation and use of a vaccine compositon for the treatment of chickenpox and/or shingles.
Previously used vaccines have generally comprised (I) an attenuated live virus type of vaccine in which the virus has been rendered avirulent but not killed by some form of genetic attenuation; or (II) specific viral components isolated and purified from the virus and inactivated by formalin or some other chemical or physical treatment.
The present invention contemplates Type II vaccines, wherein the specific viral components isolated and purified from the virus and inactivated by formalin or other treatments are contemplated to be secretory truncated VZV gp. Unless otherwise specified in the Specification and Claims, VZV gp means VZY gpI, gpII, gpIII, gpIV or gpv. Furthermore, “truncatedW.as used in the specification and Claims is defined as a segment of indeterminate size of the VZV gp_(but' not the full-sized VZV 9P) wherein a substantial portion (or all) of the amino acid sequence.ceterminal of the region has~»» sbeen_deleted. .The present invention alsorcontemplates-theiap preparation of recombinant secretory truncated Vzvngp for use in a vaccine against VZV. ' 3 ' ' .In another embodiment, the present intention is directed to a Type II vaccine which contains secretory. truncated VZV gp.
By vaccine is meant an agent used to stimulate the ,immune system of a living organism so that immunological protection against future harm caused by an infectious.agent is provided. Administration.o£ a vaccine contemplated by the present invention to the patient (or animal) may be by any known or standard techniques. These include oral ingestion, intestinal intubation, or broncho-nasal spraying. other methods of administration, such as intravenous injection, that allow the carrier microbe to reach the human or animal's bloodstream may be acceptable when the carrier microbe is unable to reproduce.
In a further embodiment, the present invention contemplates a diagnostic assay for VZV, and additional1y,_a diagnostic kit for the detection of VZV antibody in various clinical manifestations of VZV infection and in vaccinated individuals.
The present invention represents a step forward from earlier attempts to obtain VZV gp protein. Previously, the known gene for VZV gpI was inserted into a plasmid and incorporated into a vaccinia virus expression system.
However, the VZV gpI produced by this expression system remained intracellular, i.e., within the mammalian ce1ls,' thus failing to permit antigenic activity (the production of antibodies). The discovery of_the present invention is an expression vector in vaccinia virus capable of producing, i.e.,_expressing a truncated VZV gp such as. for example, gpl,~gpII, gpIII, gpIV or.gpV, which is secreted fromf ; mammalian-cells. This.truncated gp further contains an epitope which causes the production-of neutralizing antibodies in invaded hosts. The VZV gp gene is cloned in pGEM transcription vector, cleaved with restriction enzymes. such as, for erample, EcoRI and Bgl II=restriction:enzymes (to remove part or substantially all of the C—termina1 region), blunt-ended and cloned at the Smal site of vaccinia virus insertion vector pSC11.as shown in Figure 1.
V_ In a_preferred embodiment, the present.invention contemplates the construction of a recombinant DNA expression vector as follows. A 592-bp DNA fragment containing 17 bp from pGEM-4 polylinker upstream from SmaI site and 575 nucleotides (spanning nucleotides 115712 to 116287 of the VZV genome) is cleaved with EcoRI and Bg1II, respectively, from PGEM recombinant carrying a blunt—ended VZV BglI DNA fragment (spanning nucleotides 115712 to 118181) containing gpI open reading frame (Davison and Scott, supra, p. 1800-1801, 1986, incorporated herein by reference). The truncated gpI (TgpI) DNA, encoding the N-terminal region of gpl with 159 amino acid residues and an estimated size of 17.5 kDa, is blunt- ended and cloned at the SmaI site of pSC11 plasmid vector (Fig. 1) and inserted into vaccinia genome as described in the.Eramp1es.
The truncated gpi (Tgpl / Bglll) contains el epitope located within 14 amino acid residues between residues 109 to-123 of the Predicted amino acid sequences of VZV gpl (Vafai, et al., supra, 1988; Vafai, et al., supra, 1989). The TgplBglll lacks the 464 amino acid residues at the C-terminal region of gpl, which apparently includes the membrane-anchoring region of gpl.
In another preferred embodiment, the present invention contemplates the construction of a recombinant expression vector as follows. A 1647-bp DNA fragment containing 17 bp from pGEM-4 polylinker upstream from the Smal site and 1630 VZV nucleotides (spanning nucleotides 115712 to 117342 of the VZV genome) is cleaved with EcoR1 and Xmalll, respectively, from pGEM recombinant carrying a blunt-ended VZV Bglli DNA fragment (spanning nucleotides 115712 to 118181) and containing gpl open reading frame (Davison and Scott, supra, p. 1800-1801, 1986).
The truncated gpl (T gplxmalll) DNA, encoding the N-terminal region of gpl with 511 amino acid residues, was blunt-ended and cloned at the Smal site of pSC11 plasmid vector and inserted into the vaocinia virus genome as described in the Examples.
The Tgplxmalll lacks the 112 amino acid residues at the C-terminal region of gpl, which apparently includes the membrane-anchoring region of gpl.
The present invention is directed to a recombinant DNA expression vector as described abovevwhich includes a nucleotide sequence capable of expressing‘. in an infected, transfected or transformed host a Tgp which is secreted extracellularly "from said host and which is capable of causing an antibody response in mammals, and preferably a mature polypeptide defined by the 159 amino acid sequence (Seq. id.
No. 1): Met Gly Thr Val Asn Lys Pro Val Val Gly Val Leu Met GIY P319 15 Gly Ile Ile Thr Gly Thr Leu Arg Ile Thr Asn Pro Val in-g Ala 30 Sr: Val Leu Arg Tyr Asp Asp Phe His Th: Asp Glu Asp Lys Leu 45 Asp Thr Asa Set Va}. '1’Y7-' 51“ 910 TY! TY?-' His 39‘ MP “is A13 60 Glu ser Ber '1‘r:p Val Asn Ax-9 Gly Glu ser. Set Arg I.-ys Ala Tyr 75 Asp His Ash sex Pro Tyr Ile Tr? P7-'0 fir‘! 35" “P TY’ “P 513' 9° Phe Leu cm Asn Ala His c1u His His G1? Val TY!‘ Mn '31“ 91? 1°5 1 M-9 c;1y_11e Asp Se: Gly Glu Arg Len Hat Gln Pro Thr Gln Bet 120 Set Ala cm Glu Asp Leu Gly 389 Asp Thr 61? I19 H15 "91 11° 135 Pro .'rtu5;x.eu nan Gly Asp Asp Ara His I-Y 11° V31 55“ “*1 “*9 15° Gln Arg Gln Tyr 611 Asp Val P118 1-Y5 159 or a mature polypeptide defined by the 511 amino acid sequence (Seq. Id. No. 2): The infected, transfected or transformed host contemplated by the present invention can be mammalian cells such as, for exampie, green monkey kidney celis (BSC-1), -13a- COS monkey cells, HeLa cells, hamster kidney cells and human fibrobtast ceils. in addition, any human tissue is contemplated as a suitable host. The present invention contemplates that the infected, transformed or transfected cell as described above can be caused to produce and secrete Tgp (truncated VZV glycoprotein) and preferably, TgplBglI| as defined by Seq. id. No. 1 or Tgplxmaill by the recombinant DNA expression vector of the present invention.
The present invention also contemplates other secretory Tgpls. Other Tgpls containing other immunogenic epitopes can be generated by cloning and expressing various truncated gpl genes. The other gpls can be obtained, for example, by utilising the following restriction enzymes: (21) EcoPl and EcoRI, wherein EcoPl cleaves at nucleotide 115751 and results in generation of a 276 amino acid sequence; (b) BstE2 and EcoRl, wherein BstE2 cleaves at nucleotide 116754 and results in generation of a 316 amino acid sequence; (:3) Nde1 and EcoRl, wherein Nde1 cleaves at nucleotide 116831 and results in generation of a 341 amino acid sequence; and (cl) EcoFiI and EcoRl wherein EcoRl cleaves at nucleotide 117034 and results in generation of a 408 amino acid sequence. _The various types of Tgpl contemplated by the present invention as described above are specifically constructed to eliminate that portion of the C-terminal region of the nucleotide sequence encoding the region of VZV gp which prevents the extracelluiar expression of that VZV gp (such as gpl, gpll, gplll, gpIV or gpV), i.e., apparently by eliminating the membrane anchoring region of the encoded protein. in preparing suitable expression vectors for such truncated secretory proteins, it is also necessary to maintain at least one epitope, e.g,, e1, so that the encoded Tgp (extracellularly secreted) elicits an antibody response in the host. Provided with the discovery-of the present invention one skilled in the art is able to construct various suitable expression vectors for use as vaccinesaand-detection systems, all contemplated by the present invention.W = The present invention also contemplates the modification of the recombinant DNA expression vector _described above in order to obtain other truncated VZV gps.
The discovery of the present invention is directed to deleting the native (naturally occurring) VZV DNA encoding the C—termina1 region of gpII, gpIII, gpIV or gpv, as described above for gpI, resulting in the production of TgpII, TgpIII, TgpIV or Tgpv, which can be secreted outside of mammalian cells and resulting in antigenic activity, in gigg, i.e., stimulating antibody formation.
The present invention also contemplates a process for producing a secretorv truncated Varicella-zoster virus gp. This process consists of the following steps: _sequence into said polypeptide. a) providing a vector comprising a nucleotide sequence coding for said polypeptide, wherein the nucleotide sequence is capable of being expressed by a host containing the vector, and wherein the nucleotide sequence is selected from the group of nucleic acids capable of encoding with a continuous nucleotide sequence a Varicella-zoster virus gp wherein a-substantial portion of VZV gp Cterminal region of the gp is genome coding for the deleted and wherein said gp is secreted extracellularly from said host and'includes at least one epitope effecting an antibody response in a mammalian host, and such as, for example, a polypeptide of the open wreading frame defined by the 159 amino acid sequence of Seq.
Id. No. I or a polypeptide of the open reading frame defined by the I59 amino acid sequence of Seq. Id. No. 2; incorporating the vector into the host; and maintaining the host containing the vector under conditions suitable for expression of the nucleotide This process can include a promoter operationally associated with said nucleotide sequence. This process further contemplates said nucleotide sequence including a region of nucleotides capable of encoding a leader sequence.
The expression of recombinant vaccinia virus carrying the TQP (VVTQP) can be analyzed by infection of, for example, BSC-1 cells with Tgp such as, for example, VVTgpI, and immunoprecipitation of cell lysates with a panel of MAbs prepared against VZV gpl, gpII, gpIII, gpIV and a VZV seropositive human serum or other conventional means known to those skilled in the art. "with respect to the fact that said Tgp is secreted from the infected cells, cells can be infected with Tgp such as, for example, VVTgpI, and radioactively-labeled.
Antibodies against Tgp such as, for example, VVTgpI, can be generated in, for example, rabbit (e.g., RAnti—VVTgpI as described in the Examples). These antibodies can be tested to determine whether Tgp such_as, for example, vVTgpI, is capable of inducing antibody response-which is recognized by VZV gp. Mammalian cells such as, for example, jBSC—l cells can be-infected with VZV and radioactive1y~’ "labeled in the absence or presence of tunicamycinicvafai} et 1 -31., 1989); The Tgp of the present invention is papab1e.o£' inducing antibody response which is recognized by native epitope (such as e1 as found in Tgpl defined by—Seq._Id.-No. 1) and is capable of neutralizing VZV infectivity in the presence of complement. ’ i Vaccines of the present invention may be administered parenterally (e.g., by intramuscular, _ subcutaneous, or intravenous injection). The amount required will vary with the antigenicity of the'ggne product and need only be an amount sufficient to induce an imune response typical of existing vaccines. Routine experimentation will easily establish the required amount. Typical initial dosages of vaccine could be about 0.001-100 mg antigen/kg body weight, with increasing amounts or multiple dosages used as needed to provide the desired level of protection.
The pharmaceutical carrier in which the vaccine is suspended or dissolved may be any solvent or solid that is non-toxic to the inoculated animal and compatible with the carrier organism or antigen gene product. Suitable _ pharmaceutical carriers include liquid carriers, such as normal saline and other non—toxic salts at or near physio- logical concentrations, and solid carriers, such as talc or sucrose. Adjuvants, such as Freund's adjuvant, complete or incomplete, may be added to enhance the antigenicity via the bronchial tubes, the vaccine is suitably present in the form of an aerosol. Booster immunizations may be repeated numerous times with beneficial results.
The present invention is also directed to a method for stimulating an immune response to chickenpox and shingles in a mammalian host. This method consists of administering an ef£eetive.amount.of secretory VZV Tgpw1e.g.,“TgpI,,TgpII, TgpIII,;TgpIV or Igpv) under conditions su£ficient_t6 cause the production of antibodies to said1Tgp,¢which’are'we1l recognized_by one of ordinary skill in the art. ‘The dosage effective amount is.0.001—100 mg of secretory VZV TQP/kg body weight.
The subject invention also encompasses antibodies, either monoclonal or polyclonal, which are useful in the therapeutic control of chickenpox and/or.shing1es- Said antibodies_can_be prepared as described above and by injecting mammalian species, e.g., human,.horse, rabbit, sheep, mice, etc. with inactivated Tgp or derivatives thereof ‘and then purifying said antibodies employing the detection systems contemplated and described in further detail below.
In another embodiment, the present invention relates to the development of specific human or other (e.g., African green monkey kidney cells, COS monkey cells, HeLa cells or Chinese hamster cells) polyclonal or monoclonal antibodies raised against secretory VZV Tgp (I, II, IIl, IV or V), as well as human-mouse chimeric polyclonal or monoclonal antibodies for administration in passive immunization against chickenpox and/or shingles.
Immunization refers to the process of inducing a continuing high antibody level in an organism i.e., in humans, which is directed against an antigen to which the organism has been previously exposed.
Eembodiment of“the?present ffiVenEion.’f””" gtechniques. .immune-system; Passive immunization, as defined herein, refers to resistance (e.g., temporary or sustained protection against infection) based on giving preformed antibodies to a patient from an in fiiyg or in'vitro source. The maih advantage of passive immunization is the prompt availability of large amounts of antibodies against Vzv as aes¢i:5aan:n*£5s ‘ human-mouse chimeric antibody is produced by oomhining the Fab.portion of the mouse imunoglobulin gene and £52-Fe portion of the human immunogiobulin gene by recombinant DNA ' The Production of human-mouse chimeric’ o'x antibodies is advantageous since large amounts of antibodies .can be produced by this system and human—mouse chimeric ‘antibodies can be recognized by‘cei1s of“the human?immune isystem whereas non4chimeric—antibodies would not be" i The present invention further contemplates the use of the above—described antibodies in a detection assay (immunoassay) for VZV.
A wide range of immunoassay techniques are available for utilization in the present invention as shown by reference to U.s. Patent Nos» 4,016,043; 4,424,279;- 4,018,653 and by Harlow. et al., supra. This, of course,* includes both single-site-and two—site, or "sandwich", assays of the non-competitive types, as well as in traditional Sandwich assays are among the A number of variations of the: technique exist, and all are intended to he the present invention. typical forward assay, an unlabeled antibody-' in a solid substrate and the sample to be‘ tested brought into contact with the bound molecule. After a suitable period of incubation, for a period of time ' sufficient to allow formation of an antibody-antigen binary invention. sandwich assay encompassed by In a complex, a second antibody, labeled with a reported molecule_' capable of producing a detectable signal is then added and incubated, allowing time sufficient for the formation of a ternary complex of antibody—1abe1ed antibody. Any unreacted material is washed away, and the presence of the antigen is determined by observation of the visible signal produced by the reported molecule. 'The results may either be qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of hapten.
Variations on the forward assay include a simultaneous assay, in which both sample and labeled antibody are added simultaneously to the bound antibody, or a reverse assay in which the labeled antibody and sample to be tested are first combined, incubated and then added to the unlabeled surface bound antibody. These techniques are well known to those skilled in the art, and the possibility of minor variations will be readily apparent to those skilled in the art.
As used herein, “sandwich assay" is intended to encompass all variations on the basic two—site technique.
For example, these antibodies may be used to detect secretory Tgp, e.g., Tgpl, -'Tgp;II, TgpIII, TgpIV, Tg.pV or-more’: 1 . specifically, secretory gpI as defined byJSeq;:1d;vNo: 1, by- use of specific antigenic determinants Le;g.,=el epitope) as_ immobilized immunoadsorbants. .Serum is obtained from subjects to be tested and said serum contacted to the immobilized viral immunoadsorbants. If said serum contains antibodies to said imunoadsorbants, an antibody~adsorhant conjugate will result. After removing excess serum and non- bcund antibodies, a second antibody specific.to a first antibody, said first antibody-being capable of forming a conjugate with said immunoadsorbant, is added thus resulting in a double antibody-adsorbent conjugate. This double antibodyvadsorbant conjugate will only result if the test serum contains antibodies to the imunoadsorbant.
Consequently, standard detection techniques can be used to identify the conjugate.
E In another immunoassay, the competitive binding assay, a limiting amount of antibody specific for the molecule of interest (either an antigen or hapten) is combined with specific volumes of solutions containing an unknown amount of the molecule to be detected and a solution containing a detectably labeled known amount of the molecule to be detected or an analog thereof. Labeled and unlabeled molecules then compete for the available binding sites on the antibody. Phase separation of the free and antibody—bound molecules allows measurement of the amount of label present in each phase, thus indicating the amount of antigen or hapten in the sample being tested. A number of variations in this general competitive binding assay currently exist.
In any of the known immunoassays, for practical purposes, one of the antibodies to the antigen (secretory truncated VZV gp) will be typically bound to a solid phase".—»* and a second molecule, either theisecond antibody in a:. esandwich assay, or, in a competitive assay, the known amount" —‘ of antigen, will bear a detectable label or reporter molecule in order to allow visual detection of an antibody—antigen reaction. when two antibodies are employed, as in the sandwich assay, it is only necessary that one of the antibodies be specific for, e.g., secretory truncated VZV gpI, II, III, IV or V. The following description will relate to a discussion of a typical-forward sandwich assay; however, the general techniques are to be understood as being applicable to any of the contemplated imunoassays.* =In the typical forward sandwich assay, a first antibody having specificity for, e.g., secretory Tgpl, II, III, IV or V or the mature polypeptide as defined by Seq. Id.
No. 1 or its antigenic fragments is either covalently or passively bound to a solid surface. typically glass or a polymer, the most comonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. be in the form of tubes, beads, discs or microplates, or any The binding processes are well-known in the art and generally consist of cross—1inking, covalently binding, or physically adsorbing the molecule to the insoluble carrier. Following binding, the po1ymer—antibody complex is washed in preparation for the test sample. An aliquot of the sample to The solid surface is The solid supports may other surface suitable for conducting an immunoassay. be tested is then added to the solid phase complex and incubated at 25°C for a period of time sufficient to allow binding of any subunit present in the antibody. The ihcubation_period will vary, but will generally be in the range of about 2-40 minutes. Following the incubation period, the antibody subunit solid phase is washed and dried and incubated with a second antibody specific for a portion of the haptenfivglhe second antibody is linked to a reporter‘ molecule ‘which-:_is used to indicate the bi___ndin‘g_,_ of the‘ second antibody to the hapteni . p dBy "reporter molecule", as used in the present specification and claims, is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of antigen-bound antibody.
Detection may be either qualitative or quantitative. The most commonly used reporter molecules in this type of assay are either enzymes, fluorophores or radionuc1eotide— containing molecules. ’ In the case of an enzyme immunoassay (EIA), an enzyme is conjugated to the second antibody, generally by - means of glutaraldehyde or periodate. As will be readily recognized, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan. Commonly used enzymes include horseradish peroxidase, glucose oxidase, beta—galactosidase and alkaline phosphates, among others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable color change. For example, p-nitrophenyl phosphate is suitable for use with alkaline phosphatase conjugates; and for peroxidase conjugates; 1,2—phenylenediamine, 5-amino- salicyclic acid, or tolidine are commonly used. It is also possible to employ fluorogenic substrates, which yield a fluorescent product rather than the chromogenic substrates noted above.
The enzyme—1abeled antibody is added to the firstj antibody hapten complex, allowed to bind, and then excess" reagent is washed away. A solution containing the , appropriate substrate is then added to the ternary complex of antibodyeantigensantibody4- 1he:substrate will react with the ’ Aenzyme linked to the second antibodyfigiving afiqualitative visual signal, which may be further quantitated, usually‘ spectrophotometrically, to give an indication of the amount of hapten which was present in the sample.. ' 'A1ternately, fluorescent compounds, such-as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. when activated by illumination with light of’a particular‘ wavelength, the fluorochrome-labeled antibody absorbs the light energy, inducing a state of excitability in the molecule, followed by emission of the light at a characteristic color visually detectable with a light microscope. As in the EIA, the fluorescent labeled antibody is allowed to bind to the first antibody—hapten complex.
After washing off the unbound reagent, the remaining ternary complex is then exposed to the light of the appropriate wavelength, the fluorescence observed indicates the presence of the hapten of interest. Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. other reporter molecules, However, such as radioisotope, chemi- luminescent of bioluminescent molecules, may also be employed. It will be readily apparent to the skilled technician how to vary the procedure to suit the required purposes. it will also be apparent that the foregoing can be used to detect directly or indirectly (i.e.. via antibodies) VZV.
The present invention also contemplates a method of diagnosing VZV comprising contacting serum, tissue or tissue extracts of an individual to be tested with an antibody against secretory truncated VZV gp (such as, for example, ggpl, gpll, gplli, gplv or gpv) or an active fragment thereof, for a time and under conditions necessary to form an antibody-antigen complex, and then detecting any resultant antibody--antigen complex. Such conditions would be well recognized by an artisan of ordinary skill in the art.
In a further embodiment, the present invention also relates to a‘ kit for the detection of antibodies produced in response to secretory Tgp (such as, for example, Tgpl, Tgpll, Tgplll, Tgplv, TgpV or TgplBgl|l as defined by Seq. ld. No. .1 or TgplXrr_1a|ll as defined by Seq. id. No. 2) and its antigenic fragments (epitope(s)), the kit being compartmentalised to receive a first container adapted to contain an antibody having specificity for said antibody to Tgp or fragments thereof and a second container containing an antibody specific for first antibody and being labelled with a reporter molecule capable of giving a detectable signal. if the reporter molecule is an enzyme, then a third container, containing a substrate for said enzyme is provided.
The diagnostic kit of the present invention can be used to detect the antibody status of VZV glycoproteins. This kit represents a rapid method of diagnosis and detection of VZV in individuals exhibiting various clinical manifestations of VZV as well as in vaccinated individuals.
EXAMPLES 1) Materials And Methods ,.Varice11a—zoster virus (VZV) strain VZV86, originally isolated from a patient with zoster, was grown and propagated in African green monkey kidney cells (BSC-1) by the cocultivation method described in Vafai et al., Virus ~ ggg; lg: 319-336 (1989). Vaccinia virus (strain IHDJ) was grown in BSC-1 cells at’a multiplicity of infectioni(mto.i.) of 0.01 plaque forming units (PFU) as described in Cabirac, et al.V, Virus Res. _1g=2'o5-214 (1988).
) Preparation of Monoclonal and.Po1yc1ona1 Antibodies Monoclonal antibodies (MAbs) against VZV g1yco—- - described in Vafai et a1., Virus Res. 1:325-333 (1987).
) Construction of Recombinant Vaccinia Virus Fig. 1 illustrates the construction of the Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1982)), and ligated into the Smal site of the insertion vector pSC11(Chakrabarti, et al., , 5: 3403-3409 (1985)). The recombinant plasmid was designated pVVTgplBg|l'l (and is shown in Fig. 1). The recombinant vaccinia virus was generated by the method described by Mackett, et al. “The Construction and Characterisation of Vaccinia Virus Recombinants Expressing Foreign Genes” in (D. M. Glover, ed.), iRL Press, Oxford, p. 191-211 (1985) with modifications. 143B TK' cells (Mackett, et al., 1985) were grown overnight in the absence of bromodeoxyuridine (BudR), and were then infected with vaccinia virus (strain IHDJ) at a m.o.i. of 0.01 PFU and incubated at 37"C for 90 min. Infected cells were then transfected with 30 pg of pVVTgpl and 50 pg of Lipofectin reagent (BRL) according to the manufacturer's instructions. Cells were harvested 48 hours post-infection-transfection and the resulting virus stock was passaged twice in TK’ cells in the presence of 25 pg/ml BudR. Recombinant vaccinia virus was distinguished from spontaneous TK' virus by straining with bluo-gal (BRL) and was clonally isolated by three cycles of plaque purification.
In order to prepare a more immunogenic secretory truncated VZV gpl, the same methodology was employed with the modification that the recombinant plasmid (pGEM-4) containing the VZV gpl gene was cleaved with Xmalll at VZV nucleotide sequence 117342 and with EcoR1 (instead of Bgill and Eco R1). The truncated gpl gene, encoding the N—terminal region of gpl with 511 amino acid residues, was The recombinant plasmid was designated pVVTgplXmal|l; The recombinant vaccinia virus was generated as described above and designated V\/'l'gplXmalll. ) _ The expression of recombinant vaccinia virus carrying the truncated VZV gpl gene (designated VVTgp|Bglll and VVTgplXma|ll) were analysed by infection of BSC-1 cells with VVTgpl at a m.o.i. of 1.0 PFU. After 22-hour incubation at 37°C. infected cells were starved for methionine in methionine-free medium for 1 hour and were then labelled with [358] methionine (100 uci/ml) for 1 hour. Cells were then washed three times with cold phosphate-buffered saline and disrupted in 4 ml of lysis buffer (0.02 M sodium phosphate, pH 7.6, 0.1M NaCl, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS). Lysates were kept on ice for 2 hours and centrifuged at electroeluted, bIunt—ended and ligated into pSCll as described above. ,000 rpm in a Beckman SW60 rotor for 2 hours at 5°C. Supernatants were stored at -70°C until immunoprecipitation with monoclonal and poiyclonal antibodies prepared against VZV proteins. (See Fig:_. 2) .
The results shown in Fig. 2 demonstrate the expression of a primary translation product of 25 kDa by VVTgpIBgllI which was processed to a 32 kDa- polypeptide during 1 hour labelling period. Both 25 kDa and 32 koalproteins can be recognised by MAb79.7 which is directed against e1 epitope (Vafai, et al., 1988).
Human serum reacts with the 25 kDa species (Fig. 2, line 2) and longer exposures of the gels indicate a faint reactivity of human serum with mature form (32 kDa) of Tgpl.
The 32 kDa protein was also reacted with MAbG7 (Fig. 2, line 4) which recognises the fully glycosylated form of VZV gpl. However, MAbC1, which is directed against VZV gpl but only recognises epitope(s) other than e1, does not react with Tgpl (Fig. 2, line 3). MAbs directed against VZV gpIV (MAbG6), gpll (MAbF8) and gplll (MAbE10) do not also react with the precursor-product of Tgpl (Fig. 2, lines 5, 6, 7), indicating the specificity of Tgpl for MAb79.7.
These results indicate that the Tgpl expressed by VVTgplBg|li retains the native conformation necessary for recognition by MAb79.7 as we! as VZV seropositive human serum. The primary translation product of Tgpl of 25 kDa has been found to be larger than the expected 17.5 kDa deduced from 159 amino acid residues encoded by the Tgpl. I ) m BSC—1 cells were infected with V\fi'gpl8glll at a m.o.i. of 1.0 PFU and after '22—hour incubation period, cells were pulse—labelled with [358] methionine (300 uci/ml) for 10 min. Cells were either harvested or washed five times with serum—free medium and the label was chased for 1, 2, 3 and 7 hours. Uninfected cells were pulse-iabelled for 10 min. and chased for 7 hours. Cell iysates were prepared as described above and immunoprecipitated with MAb79.7 which is directed against VZV gplBg||l epitope (e1) (Vafai, et al., .L_‘s.Liml. 5212544-1551 (1988)) and MAbC1 which is directed against VZV gp|Bgll| but recognises epitope(s) other than e1.
Tissue culture fluids from uninfected and VVTgplBglI|-infected cells were coilected and centrifuged for 10 min. in a microfuge. Supematants were collected and after addition of equal volume of lysis buffer to each sample, the samples were centrifuged at 40,000 rpm in a Beckman SW60 rotor for 2 hours at 5°C. Supernatants were immunoprecipitated with MAb79.7 and MAbC1. (See Fig.3).
The results shown in Fig. 3 demonstrate that precursor TgplBglll (25 kDa) detected in the infected cells during a 10-min. pulse-labelling period isprocessed to a 32kDa protein species during 1 hour chase-period and that the intensity of both 25 kDa and 32 kDa bands decrease during 7 hours chase-period (Fig.3=, CL). The results also show that the mature glycosylated form of TgplBglll (32 kDa) appeared in tissue culture fluid of the infected cells within 1 hour chase-period and the intensity of the 32 kDa TgplBglll increases during a 7-hour chase-period (Fig. 3, TCF). These results indicate that the fully processed form of TgplBglll is released from the infected cells and is recognised by MAb79.7 but not MAbC1 which is directed only against gpl epitope(s) other than e1. In addition, western-blot analysis of the 32 kDa TgplBglll purified from the infected tissue culture fluids shows that secretory TgplBglll was recognised by MAb79.7.
Controls for these experiments were provided by infection of BSO-1 cells with a recombinant vaccinia virus carrying the untruncated (full-size) VZV gpl gene and expressing untruncated VZV gpl (Vvgpl) (Cabirac, et al., MiLI.is_Bes. 10: 205-214 (1988)). Pulse-chase experiments as above were performed. In contrast to V\/Tgpl, analysis of cell lysates and tissue culture fluid from Wgpl-infected cells indicated that native VZV gpl was not secreted from the infected cells (Fig. 4 ).
\“~. Antibodies to VVTgpl were generated in a rabbit by immunisation procedures described previously (Vafal, et al., Bflrusfles. Z: 325~333 (1987) and Mil:us_Res. 13: 319-336 (1989)). subcutaneously at multiple sites in the back and hind legs. After a preimmunisation bleed (for control sera) the animal received 1 x 107 PFU/ml of VVTgp|. This was followed by three weekly injections, each consisting of 1 x 10’ PFU/ml of VVTgp|.
A New Zeaiand white female rabbit was immunised V The animal was bled seven days after the last injection and the serum (designated RAnti-VVTgp|) was assayed by immunopreoipitation as described below. I (7) VZV was grown in BSC-1 cells by cocultivation and after 48 hours, infected cells were labelled with [355] methionine (300 pcilml) for 10 min. in'the absence or presence of tunicamycln (15 pg/ml). Cells were either harvested or washed three times with serum-free medium, and the label was chased in normal medium for’ 2‘ hours in the absence or presence of tunicamycin (15 pg/ml). Cells were "then washed three times with cold phosphate—buffered saline and cell lysates were prepared as described above and immunoprecipitated with RAnti-VVTgpI.
) Immunoprecipitation Cell lysates (400 ul) from uninfected, VVTgpI- Finally, 30 ul of a 10% Formalinéfixed S. aureus suspension- was added, and after 2 hours at 4°C, absorbed imune complexes were washed three times with lysis buffer and suspended in 20ul of THE buffer (50mM Tris, pH 7.4, 150 mM Nacl, 5mM EDTA). After addition of 10 ul of 3 x sample buffer (150 mM Tris, pH 7.0, 6%—SDS, 15% 2—mercaptoethanol, 0.03% bromophenol blue), the suspension was heated in boiling water for 4 min., cooled on ice, and analyzed by 8 to 12% polyacrylamide SDS—PAGE as described in Vafai, et a1., Q; viro1.~_5_g:953-959, l984 and J. Virol. g:2544—2551, 1_9'as.
(See Fig. 5.) I Cell lysates were imuunoprecipitated with MAbCl recognizes fiZ¥ gpl and gpIV and Ranti—VVTgpI B3111 and analysed by SDS-PAGE. As demonstrated in Fig.5A and B, the results show that similar to Hlbcl, RAnti-VVTgpI Bglll reacts with precursor-products of native VZV gpl in the presence or . . .= absence of tunicamycin. This shows that e1 epitope expressed by Vwrgpl Bglll induced antibody response which is-recognized by _' by VZV native gpI el epitope. 9) Neutralization Tests , .
Neutralization tests were performed by the constant virus-varying serum technique as described {Vafai, at al., 1987). Briefly, BSC-1 cells (108) were infected with VZV by cocultivation. After three days, when infected cultures showed 80-90% cytopathic effects,.cells were scraped into the tissue culture medium, centrifuged.at 2,000 x3g for 20 min. at 4°C and the cell pellet was resuspended in 4am1 of serum- free medium. The cell suspension was.dounce~homogenized (150 strokes) on ice in a Teflon—coated homogenizer. Thea homogenates were centrifuged at 800 x g for 10 min. and the supernatants were used for neutralization tests. -Aliquots (0.5 ml) containing 100-200 PFU were mixed with equal volumes-- of different dilutions {0,1:10, 1:50 and 1:100) of RAnti—' VVTgpI or rabbit anti-VZV antibodies (RAnti-VZV) prepared against VZV virions (Vafai, et al., 1987) or preimmune sera' and 0.25 ml guinea pig complement. The mixture were . incubated at 37°C for 2 hours and inoculated into 2 wells of BSC-1 cells grown in 6—we1l plates. After incubation at 37°C for 3 hours, the inoculum was removed, the cells were washed and overlaid with medium containing 2% fetal bovine serum (FBS) and incubated at 37°C for 5-7 days. Cells were then fixed with formaldehyde, stained with cresyl violet and plaques were counted as described (Vafai, et a1., 1984). i The results show a plaque reduction of, for example, 100% with 1:10 dilution of RAnti—VZV antibodies prepared against purified VZ virions (Vafai, et a1., 1987) in the presence or absence of complement and a plaque reduction of 50% with 1:10 dilution of RAnti-VVTgpI in the presence of complement. ’
Claims (2)
1. ), CO8 monkey cells, HeLa cells, hamster kidney cells, human fibroblast cells, or human tissue celis. A cell transformed or transfected by the recombinant DNA expression vector according to Claim 1, wherein said cell is "caused to produce and secrete truncated VZV gpl by the vector. A plasmid encoding a Varicella-zoster virus polypeptide, said polypeptide being selected from the group set out in Claim 1, and wherein said polypeptide is capable of being secreted extracellularly from a host and is capable of causing a VZV antibody response in a mammal. A process for producing a secretory truncated Varicella-zoster virus glycoprctein wherein the glycoprotein is a polypeptide selected from the group - set out in Claim 1 and is capable of causing a VZV antibody response in . mammals, said process comprising the steps of:- a) providing a vector comprising a nucleotide sequence coding for said A polypeptide, wherein the nucleotide sequence is capable of being" expressed by a host containing the vector; b) incorporating the vector into the host; and c) maintaining the host containing the vector under conditions suitable _ for expression of the nucleotide sequence into said giycoprotein. A: process according to Claim 5, wherein said ‘vector includes a promoter operationally associated with said nucleotide sequence. A process according to Claim 5 or 6, wherein said host is a mammalian cell and wherein said nucleotide sequence further includes a region of nucleotides which encode a leader sequence. A process according to any of Claims 5 to 7, wherein said host cells are green monkey kidney cells (BSC-1), COS monkey cells, HeLa cells, hamster kidney cells, or human fibroblast cells or human tissue cells. A process according to Claims 5-8, wherein said expression vector is a plasmid. A recombinant secretory truncated VZV gpl being a polypeptide selected from the group set out in Claim 1, and wherein said polypeptides are secreted extracellularly from mammalian cells within which said polypeptides are produced and wherein said polypeptides include at least one antigenic epitope capable of eliciting an antibody response in a mammalian host. A vaccine for immunisation against chickenpox and/or shingles comprising an effective amount of a recombinant secretory truncated VZV gpi being a polypeptide selected from the group set out in Claim 1, and a conventional vaccine carrier. The use of secretory truncated VZV gp being a polypeptide selected from the group set out in Claim 1 for the manufacture of a vaccine for stimulating an immune response to chickenpox and/or shingles. A method of diagnosing VZV comprising contacting serum, tissue or tissue extracts of an individual to be tested with an antibody against a secretory truncated VZV gp being a polypeptide selected from the group set out in claim 1 for a time and under conditions necessary to form an antibody-antigen complex, and detecting any resultant antibody-antigen complex. Secretory truncated VZV gp consisting of SEQ ID NO: 1. ‘Secretory truncated VZV gp consisting of SEQ ID NO:
2. An expression vector substantially as hereinbefore described with reference to the Examples and Drawings. A cell substantially as hereinbefore described with reference to the Examples and Drawings. A plasmid substantially as hereinbefore described with reference to the Examples and Drawings. A process substantially as hereinbefore described with reference to the Examples and Drawings. A VZV glycoprotein whenever produced by a process as claimed in any of claims 8 to 14. A vaccine substantially as hereinbefore described with reference to the Examples and Drawings. The use of a VZV glycoprotein substantially as hereinbefore described with reference to the Examples and Drawings. ' A method substantially as hereinbefore described with reference to the Examples and Drawings.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
USUNITEDSTATESOFAMERICA04/10/19900 | |||
US59276990A | 1990-10-04 | 1990-10-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
IE85834B1 true IE85834B1 (en) | |
IE913479A1 IE913479A1 (en) | 1992-04-08 |
Family
ID=24371996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE347991A IE913479A1 (en) | 1990-10-04 | 1991-10-03 | Varicella-zoster virus antigen |
Country Status (1)
Country | Link |
---|---|
IE (1) | IE913479A1 (en) |
-
1991
- 1991-10-03 IE IE347991A patent/IE913479A1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2599350B2 (en) | Vaccines containing membrane-bound proteins | |
EP0236145B1 (en) | Processes for the production of hcmv glycoproteins, antibodies thereto and hcmv vaccines, and recombinant vectors therefor | |
Kinchington et al. | The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka) | |
IE59087B1 (en) | Virus vaccine | |
Angulo et al. | Inhibition of African swine fever virus binding and infectivity by purified recombinant virus attachment protein p12 | |
TW200538153A (en) | Feline calicivirus vaccines | |
US6180369B1 (en) | Varicella-zoster virus antigen | |
Holden et al. | Identification and characterization of the ICP22 protein of equine herpesvirus 1 | |
US6610295B1 (en) | Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor | |
US5824319A (en) | Varicella-zoster virus antigen | |
JP2568384B2 (en) | Polypeptide for pseudorabies virus vaccine, method for producing the same, and vaccine containing the same | |
WO1990001546A1 (en) | Equine herpesvirus-1 vaccine | |
IE85834B1 (en) | Varicella-zoster virus antigen | |
US5352575A (en) | Pseudorabies virus protein | |
US6858385B2 (en) | Pseudorabies virus protein | |
IE913479A1 (en) | Varicella-zoster virus antigen | |
US6255078B1 (en) | Pseudorabies virus protein cross reference to related applications | |
JP2883085B2 (en) | Glycoproteins of HCMV, antibodies thereto and methods of producing HCMV vaccines, and recombinant vectors therefor |